Advanced Cancer Nanotheranostics
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Drug Development".
Deadline for manuscript submissions: closed (20 October 2023) | Viewed by 2872
Special Issue Editor
Interests: nanobiotechnology; medicinal chemistry; multimodal molecular imaging; theranosis; nanoparticles; cancer; kidney and cardiovascular diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer is still a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. Thanks to medical progress, the available therapeutic and diagnostic possibilities have increased notably in recent years. However, it is now clear that both strategies suffer from some intrinsic limitations that impact on the whole cancer management. In fact, an optimized cancer therapy should ideally deliver the right therapy, to the right target, in a controlled fashion and with minimal systemic toxicity. Furthermore, this task appears more daunting if we consider that, in cancer, the careful coordination of diagnosis and therapy is mandatory in order to finely evaluate and calibrate the applied therapies.
Nanotechnology has emerged as a powerful strategy to overcome these limitations and, in recent decades, has promoted the production of a wide set of nanoplatforms with multifunctional abilities for tumor targeting, drug loading, and controlled release. Furthermore, imaging functionalities have been coupled to these nanoplatforms, thus enabling the possibility to also diagnose cancer and monitor therapeutic progression non-invasively and in real time. Such a fusion of therapy and diagnosis promoted by nanostructured materials is known as ‘nanotheranostics’, and these multifunctional nanotools have encountered a great applicability in biomedicine and especially in the medical management of a lot of cancers.
This Special Issue will highlight the current state of the art in the exciting and highly promising area of cancer nanotheranosis.
Prof. Dr. Marco Filice
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- theranostics
- nanotechnology
- cancer
- nanomedicine
- multifunctional nanoparticle
- multimodal molecular imaging
- drug delivery
- drug targeting
- combined cancer therapy
- clinical trials
